醫學大突破！埃博拉的治療方法開始奏效

An experimental drug is helping Patients infected with Ebola survive the virus as it sweeps across the Democratic Republic of Congo, where an outbreak has already killed at least 1,800 people.

一種實驗性藥物可以幫助感染埃博拉病毒的患者存活下來，埃博拉席捲剛果民主共和國，已有至少1,800人因此喪命。

strongly positive results with the treatment made by US drugmaker Regeneron Pharmaceuticals Inc., called REGN-EB3, led investigators to stop the trial just nine months after it began and change its design, dropping the previous standard of care and another experimental therapy.

美國製藥公司再生元製藥公司研製的治療效果明顯的REGN-EB3讓研究者僅僅在9個月之後就停止了試驗並改變了試驗設計，放棄了以前的標準治療藥物和另一種實驗性療法。

Patients across the country will now get either REGN-EB3 or mAb114, a drug that's being developed by the US National Institute of Allergy and Infectious Diseases that also appeared promising.

全國的病人現在可以得到REGN-EB3或者mAb114，mAb114是國家過敏與感染性疾病研究院正在研製的一種藥物，也很有效。

The medications may help reduce deaths and encourage those who are just starting to show signs of the disease to seek care. So far, two-thirds of the people infected in the latest outbreak have died. Violence in Congo has added to the difficulties in containing the epidemic.

這些藥物有助於減少死亡人數並鼓勵那些剛開始出現症狀的人尋求治療。截止目前，最近一次埃博拉疫情中三分之二染病患者已死亡，而且剛果的暴力衝突使流行病更難控制。

"We do have now what looks like treatments for a disease which not too long ago we really had no therapeutic approach at all," said Anthony Fauci, director of the institute.

該機構負責人Anthony Fauci說：“我們現在的確好像找到了疾病的療法，而不久前我們還一點辦法都沒有。”

"We may be able to improve the survival of people with Ebola, and it may even make people more enthusiastic about coming to care."

“我們可能能夠提高埃博拉患者的存活率了，甚至還能使人們更願意前來治療。”

The study compared experimental medicines with Mapp Biopharmaceutical Inc.'s ZMapp, which was considered the standard of care after a previous trial suggested it may help reduce death rates.

這項研究將實驗性藥物和馬普生物製藥公司的ZMapp藥物進行了對比，ZMapp被認爲是標準治療藥物，此前一項試驗表明它可能有助於降低死亡率。